Correction: A costly therapeutic dilemma in tophaceous gout: Is etanercept or rasburicase preferable? [5] (multiple letters)

Reinders, M. K., Van Roon, E. N., Brouwers, J. R. B. J., Jansen, T. L. T. A., Tausche, A-K. & Schröder, H. E. 1-Mar-2005 In : Annals of the Rheumatic Diseases. 64, 3, p. 516 1 p.

Research output: ProfessionalLetter

Original languageEnglish
Pages (from-to)516
Number of pages1
JournalAnnals of the Rheumatic Diseases
Issue number3
StatePublished - 1-Mar-2005


  • allopurinol, antigout agent, etanercept, probenecid, rasburicase, tumor necrosis factor, tumor necrosis factor inhibitor, unclassified drug, uric acid, drug cost, drug efficacy, gout, human, kidney function, letter, priority journal, tophaceous gout, uric acid blood level

View graph of relations

ID: 48105566